Combination therapy of 7-O-succinyl macrolactin A tromethamine salt and temozolomide against experimental glioblastoma

• Published in: Oncotarget Vol. 9; no. 2; pp. 2140 - 2147
• Main Authors: Jin, Jun, Hwang, Kihwan, Joo, Jin-Deok, Han, Jung Ho, Kim, Chae-Yong
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 05.01.2018
• Subjects: Research Paper; migration; macrolactin A; SMA salt; glioblastoma; invasion
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.23295

7-O-succinyl macrolactin A has shown anti-inflammatory, anti-angiogenesis, and anti-metastatic effects. It also exhibits strong suppression of tumor growth. In our previous study, we assessed the anti-neoplastic effects of 7-O-succinyl macrolactin A tromethamine salt (SMA salt) on a glioma cell line. Moreover, according to our data, SMA salt might be contributed to the inhibitory effects on migration and invasion, as well as a cytotoxic effect on the glioblastoma cell lines. In the present study, we investigated the anti-tumor effects of combination therapy with SMA salt and temozolomide (TMZ) in glioblastoma cell lines. The combination therapy affected cell viability significantly, decreasing in glioblastoma cell lines. In cell migration assays, combination therapy showed more inhibitory effects than TMZ in these cell lines. The tumor volume was significantly decreased in the combination group compared with both TMZ and control groups by using the orthotopic mouse model. The effects of combination therapy with SMA salt and TMZ attributed to the inhibition of migration, invasion activities and anti-tumor effects. SMA salt could be one of the promising candidates for combination therapy in clinical settings.